Abvc Biopharma (ABVC) Times Interest Earned (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Times Interest Earned came in at -$0.72 in Q1 2026, down 586.97% YoY from $0.15 in Q1 2025, and up 88.75% on a QoQ basis from -$6.43 in Q4 2025.
Abvc Biopharma (ABVC) Times Interest Earned (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 16 years of Times Interest Earned data on file, last reported at -$0.72 in Q1 2026.
- Quarterly Times Interest Earned fell 586.97% year-over-year to -$0.72 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.69 (down 849.75% YoY) and the FY2025 annual result came in at -$17.2, down 201.82% from the prior year.
- Times Interest Earned grew to -$0.72 in Q1 2026, from -$6.43 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of $0.38 in Q4 2023 to a low of -$141.84 in Q1 2022.
- A 5-year average of -$19.22 and a median of -$0.47 in 2024 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned soared 101.62% — and 2025, when it plunged 1432.79%.
- Tracing ABVC's Times Interest Earned over 5 years: stood at -$23.3 in 2022, then jumped by 101.62% to $0.38 in 2023, then plunged by 332.33% to -$0.88 in 2024, then slumped by 633.56% to -$6.43 in 2025, then surged by 88.75% to -$0.72 in 2026.
- The last three Times Interest Earned figures came in at -$0.72 (Q1 2026), -$6.43 (Q4 2025), and -$7.14 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.42 |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | -18.42 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.10 |
| Mar 31, 2026 | -0.72 |
| Dec 31, 2025 | -6.43 |
| Sep 30, 2025 | -7.14 |
| Jun 30, 2025 | -0.34 |
| Mar 31, 2025 | -0.11 |
| Dec 31, 2024 | -0.88 |
| Sep 30, 2024 | -0.47 |
| Jun 30, 2024 | -0.14 |
| Mar 31, 2024 | -0.45 |
| Dec 31, 2023 | 0.38 |
| Sep 30, 2023 | -0.34 |
| Jun 30, 2023 | -0.35 |
| Mar 31, 2023 | -0.25 |
| Dec 31, 2022 | -23.30 |
| Sep 30, 2022 | -5.73 |
| Jun 30, 2022 | -138.69 |
| Mar 31, 2022 | -141.84 |
| Dec 31, 2021 | -1,034.69 |
| Sep 30, 2021 | -94.59 |